Results 1 to 10 of about 17,217,890 (291)

The role of immunotherapy in non-clear cell renal cell carcinoma [PDF]

Frontiers in Oncology, 2023
The category of non-clear cell renal cell carcinoma (nccRCC) includes several clinically, histologically, and molecularly diverse entities. Traditionally, they comprise type 1 and type 2 papillary, chromophobe, unclassified, and other histologies ...
Carla Climent, Sandra Soriano, Teresa Bonfill, Natalia Lopez, Marta Rodriguez, Marina Sierra, Pablo Andreu, Monica Fragio, Mireia Busquets, Alicia Carrasco, Ona Cano, Miguel-Angel Seguı́, Enrique Gallardo   +12 more
doaj   +6 more sources

The incidence, pathogenesis, and management of non-clear cell renal cell carcinoma [PDF]

Therapeutic Advances in Urology
Renal cell carcinoma (RCC) is the most common type of kidney cancer and is divided into two distinct subtypes, clear cell renal cell carcinoma (ccRCC) and non-clear cell renal cell carcinoma (nccRCC).
Priyanka Naik, Harshitha Dudipala, Yu-Wei Chen, Brent Rose, Aditya Bagrodia, Rana R. McKay   +5 more
doaj   +6 more sources

Characterizing Tumor Thrombus Arising from Non–Clear Cell Renal Cell Carcinoma [PDF]

European Urology Open Science, 2022
Background: Renal cell carcinoma (RCC) can exhibit a unique vascular tropism that enables tumor thrombus extension into the inferior vena cava (IVC). While most RCC subtypes that form tumor thrombi are of clear cell (cc) histology, non–clear cell (ncc ...
Matthew J. Rabinowitz, Tina Esfandiary, Joseph Cheaib, Sunil H. Patel, Ridwan Alam, Meredith Metcalf, Dmitry Enikeev, Phillip M. Pierorazio, Yasser M.A. Ged, Mohamad E. Allaf, Nirmish Singla   +10 more
doaj   +2 more sources

Evolving treatment paradigm in metastatic non clear cell renal cell carcinoma

Cancer Treatment and Research Communications, 2020
The treatment landscape for renal cell cancer (RCC) has evolved tremendously over the last two decades. Treatment algorithms have shifted from the highly toxic drugs with marginal benefit to better tolerated and more effective targeted therapy drugs. The
Shuchi Gulati, Errol Philip, Sabrina Salgia, Sumanta K. Pal   +3 more
doaj   +3 more sources

Integrative Analysis of Germline Rare Variants in Clear and Non–clear Cell Renal Cell Carcinoma [PDF]

European Urology Open Science
Background and objective: Previous germline studies on renal cell carcinoma (RCC) have usually pooled clear and non–clear cell RCCs and have not adequately accounted for population stratification, which might have led to an inaccurate estimation of ...
Seung Hun Han, Sabrina Y. Camp, Hoyin Chu, Ryan Collins, Riaz Gillani, Jihye Park, Ziad Bakouny, Cora A. Ricker, Brendan Reardon, Nicholas Moore, Eric Kofman, Chris Labaki, David Braun, Toni K. Choueiri, Saud H. AlDubayan, Eliezer M. Van Allen   +15 more
doaj   +2 more sources

Efficacy and safety of combination immunotherapy for treating advanced non-clear cell renal cell carcinoma: A multicenter retrospective study in Japan [PDF]

Scientific Reports
This study aimed to evaluate the outcomes of patients with advanced renal cell carcinoma (aRCC) who were histologically diagnosed with non-clear cell carcinoma (nccRCC) and received combination immunotherapy.
Koji Iinuma, Yuta Sano, Kohei Nishikawa, Tomoki Taniguchi, Aika Matsuyama, Kaori Ozawa, Takashi Ishida, Kosuke Tochigi, Masataka Tamura, Yasuaki Kubota, Shusuke Akamatsu, Takahiro Inoue, Takuya Koie   +12 more
doaj   +2 more sources

Patient Characteristics and Survival Outcomes of Non-Metastatic, Non-Clear Cell Renal Cell Carcinoma [PDF]

Frontiers in Oncology, 2022
BackgroundNon-clear cell renal cell carcinoma (ccRCC) includes histologically and molecularly distinct subtypes such as papillary, chromophobe, collecting duct, and sarcomatoid RCC, with an incidence ranging from 20% to 25%.
Josiah An, Vignesh T. Packiam, Adithya Chennamadhavuni, Jordan Richards, Jayanshu Jain, Sarah L. Mott, Rohan Garje   +6 more
doaj   +2 more sources

Serum soluble B7-H4 is a prognostic marker for patients with non-metastatic clear cell renal cell carcinoma. [PDF]

PLoS ONE, 2018
BACKGROUND:B7-H4 is a member of the B7 family of immune-regulatory ligands and is considered to be a negative regulator of the immune response. We investigated the clinical significance of serum soluble B7-H4 in patients with non-metastatic clear cell ...
Takeshi Azuma, Yujiro Sato, Tetsukuni Ohno, Miyuki Azuma, Haruki Kume   +4 more
doaj   +2 more sources

Recent progress in non-clear cell renal cell carcinoma: biology and therapeutic strategies [PDF]

Therapeutic Advances in Medical Oncology
Non-clear cell renal cell carcinomas (nccRCC) comprise a heterogeneous group of rare malignancies, accounting for approximately 20% of all kidney cancers.
Ahmet Yildirim, Marcus W. Moses, Margo Gerke, Yash Jani, Jillian C. Thompson, Umut Akova, Mehmet A. Bilen   +6 more
doaj   +2 more sources

Advanced Treatments in Non-Clear Renal Cell Carcinoma

Urology Journal, 2011
PURPOSE: To focus on the use of targeted therapies against the non-clear histologic subtypes of renal cell carcinoma (RCC); papillary I and II, chromophobe, and collecting duct.
Hassan Errihani, Hind M’Rabti, Mohamed Fadl Tazi, Youness Ahellal, Ismail Essadi, El Mehdi Tazi   +5 more
doaj   +3 more sources